Alumis (ALMS) stock exploded higher on Tuesday after the biotech firm reported promising Phase 3 results for envudeucitinib, its candidate treatment for psoriasis.
In the late-stage trial, envudeucitinib helped patients experience symptom improvement that “rank among the strongest reported for an oral therapy,” the company said in its press release.
While ALMS shares reversed nearly half of their intraday gains by market close on Jan. 6, at one point, they were seen trading at a high of $22.30.
The Phase 3 readout is a “game-changer” for Alumis shares as envudeucitinib met all primary and secondary endpoints, delivering superior skin clearance rates compared to existing therapies.
For investors, this isn’t just another clinical win, it positions ALMS as a serious contender in the multibillion-dollar psoriasis market, currently dominated by Bristol Myers (BMY) and Johnson & Johnson (JNJ).
In fact, the rapid onset of efficacy, with meaningful improvements seen as early as week four, underscores the drug’s potential to redefine treatment standards.
If regulatory approval follows, Alumis could secure a foothold in one of the largest immunology markets, transforming its profile from a speculative biotech name to a legitimate growth story.
While ALMS stock closed significantly lower than its intraday high on Jan. 6, signaling much of the rally was actually sentiment-driven, there’s reason to own this biotech name for the long term
With psoriasis representing a global market worth tens of billions of dollars annually, even modest penetration could trigger significant upside.
Plus, the firm’s pipeline includes additional immunology assets, offering diversification beyond psoriasis.
In short, Alumis offers early stage exposure to multiple advanced therapeutic markets at a time when the overall sentiment on biotech is seen improving in 2026.
According to Barchart, bullish options contracts expiring mid-April indicate potential for a 15% rally from here, which means ALMS could be trading near $19 within the next four months.
